Press Release Sep 09 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release regarding the in-licensing of a critical drug for chronic kidney disease patients from Pharmacosmos A/S of Denmark. The drug, MonoFerric, is an iron isomaltoside injection indicated for treating iron deficiency when oral preparations are ineffective. This acquisition allows Zydus to market MonoFerric in India and Nepal, enhancing their portfolio in the nephrology segment. The press release emphasizes the importance of addressing iron deficiency, particularly in chronic kidney disease patients.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Sep 07 2022
- Press Release Aug 31 2022
- Press Release Aug 30 2022
- Press Release Aug 11 2022
- Press Release Aug 05 2022
Later from Zydus Lifesciences
- Press Release Sep 12 2022
- Press Release Sep 13 2022
- Press Release Sep 16 2022
- Press Release Sep 20 2022
- Press Release Oct 01 2022
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences